{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.9","upperLimit":"78.0","value":"54.5"},{"groupId":"OG001","lowerLimit":"12.8","upperLimit":"96.1","value":"75.0"},{"groupId":"OG002","lowerLimit":"100","upperLimit":"100","value":"100.0"},{"groupId":"OG003","lowerLimit":"30.5","upperLimit":"70.0","value":"52.2"},{"groupId":"OG004","lowerLimit":"33.4","upperLimit":"97.9","value":"85.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"7"}],"units":"Participants"}],"description":"Percentage of participants with OS at 12 months are reported. The OS is defined as the time from the first dose of tabelecleucel or EBV-CTLs to the date of death due to any cause. The OS was estimated using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with EBV+ PTLD following HCT who were R/R to rituximab received IV infusion of tabelecleucel on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only)"},{"description":"Participants with EBV+PTLD following SOT who were R/R to rituximab and chemotherapy received IV infusion of tabelecleucel on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only)"},{"description":"Participants with EBV+ following LMS received IV infusion of tabelecleucel on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"EBV+ LMS (Tab-cel Only)"},{"description":"Participants with EBV+PTLD following HCT who were R/R to rituximab or rituximab naive received donor-derived EBV-CTLs on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only)"},{"description":"Participants with EBV+ following viremia received donor-derived EBV-CTLs on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"EBV+ Viremia (EBV-CTLs Only)"}],"paramType":"NUMBER","populationDescription":"Full analysis set included all participants who received at least one dose of study treatment (tabelecleucel or EBV-CTLs). Results from arms with \\<= 3 participants (as shown in the participant flow) are excluded due to the low numbers of participants; these low numbers pose a risk for participant re-identification in these rare indications of this single center study.","reportingStatus":"POSTED","timeFrame":"From Day 1 through 12 months after Day 1 dose","title":"OS Rate at 12 Months","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}